Evidence map›Paper›PMID 36676118›Full record

ReviewLife (Basel, Switzerland)2023

Multimodality Imaging in Sarcomeric Hypertrophic Cardiomyopathy: Get It Right…on Time.

Alessandro Galluzzo, Francesca Fiorelli, Valentina A Rossi, Luca Monzo, Giulia Montrasio, Massimiliano Camilli, Geza Halasz, Giuseppe Uccello, Rocco Mollace, Matteo Beltrami

Open access · goldAbstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 4 countries.

Alessandro GalluzzoCardiology Unit, Santa Croce Hospital, 10024 Moncalieri, Italy.ORCID 0000-0003-2803-6761
Francesca FiorelliRoyal Brompton and Harefield Hospitals, Part of Guy's and St. Thomas' NHS Foundation Trust, London SW3 6NP, UK.
Valentina A RossiDepartment of Cardiology, University Hospital of Zurich, 8091 Zurich, Switzerland.ORCID 0000-0001-9235-6597
Luca MonzoCentre d'Investigations Cliniques Plurithématique, Université de Lorraine INSERM, 54035 Nancy, France.ORCID 0000-0003-2958-943X
Giulia MontrasioInherited Cardiovascular Diseases Unit, Barts Heart Centre, St. Bartholomew's Hospital, London EC1A 7BE, UK.
Massimiliano CamilliDepartment of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.
Geza HalaszDepartment of Cardiosciences, A.O. San Camillo-Forlanini, 00152 Rome, Italy.
Giuseppe UccelloCardiology Unit, Medical Department, "Galeazzi-Sant'Ambrogio" Hospital, 20157 Milan, Italy.ORCID 0000-0002-6163-8468
Rocco MollaceCardiovascular Department, Humanitas Gavazzeni, 24125 Bergamo, Italy.ORCID 0000-0002-7106-5595
Matteo BeltramiCardiology Unit, San Giovanni di Dio Hospital, 50143 Florence, Italy.ORCID 0000-0001-7161-3224
Guy's and St Thomas' NHS Foundation Trust · GBHumanitas Gavazzeni · ITInserm · FRIstituto Clinico Sant'Ambrogio · ITNuovo Ospedale San Giovanni di Dio · ITSt Bartholomew's Hospital · GBUniversità Cattolica del Sacro Cuore · ITUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) follows highly variable paradigms and disease-specific patterns of progression towards heart failure, arrhythmias and sudden cardiac death. Therefore, a generalized standard approach, shared with other cardiomyopathies, can be misleading in this setting. A multimodality imaging approach facilitates differential diagnosis of phenocopies and improves clinical and therapeutic management of the disease. However, only a profound knowledge of the progression patterns, including clinical features and imaging data, enables an appropriate use of all these resources in clinical practice. Combinations of various imaging tools and novel techniques of artificial intelligence have a potentially relevant role in diagnosis, clinical management and definition of prognosis. Nonetheless, several barriers persist such as unclear appropriate timing of imaging or universal standardization of measures and normal reference limits. This review provides an overview of the current knowledge on multimodality imaging and potentialities of novel tools, including artificial intelligence, in the management of patients with sarcomeric HCM, highlighting the importance of specific "red alerts" to understand the phenotype-genotype linkage.

Indexed as

hypertrophic cardiomyopathyimagingleft ventricular diastolic dysfunctionleft ventricular systolic dysfunctionoutcomephenocopies

Identifiers

PMID36676118
PMCPMC9863627
OpenAlexW4313646486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.